Opthea (OPT) Short Interest
Opthea (ASX:OPT) had 0.01% of shares reported as short positions as of 13 July 2026, representing 70,621 shares. Opthea operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Opthea
Opthea is a biopharmaceutical company focused on developing innovative biologics-based therapies for treating vision-threatening eye diseases. The company is pioneering the development of sozinibercept, a first-in-class VEGF-C/D 'trap' inhibitor, aimed at improving treatment outcomes for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Short position
Opthea (ASX:OPT) has 0.01% of its shares on issue reported as short positions as of 13 July 2026, or about 70,621 shares. Over the past 30 days that figure has fallen 0.48 percentage points, and over 90 days it has fallen 1.92 percentage points. Its highest recorded short interest was 4.46% in March 2025. OPT is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 35, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4OPT intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Opthea
About
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss OPT
Start a research thread or post the first pulse update